Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tongjitang Reports Zero Net Operating Income for Q4

publication date: Mar 10, 2008

Tongjitang Chinese Medicines Company said that share-based compensation costs took its net operating income down to almost zero in the fourth quarter. Without special charges, which include share-based compensation and other public company-related charges, Tongjitang would have reported net operating income of 55.2 million RMB ($7.6 million), a 55% improvement over the 35.5 million RMB ($4.9 million) the company earned in Q4 of 2006. The disappointment came on the same day the company's CEO announced a $10.20 per ADS offer for the company.  More details...

Stock Symbol: (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital